{"preliminary_commentary":{"by_channel":{"x_thread":2,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"name":"LuCarbo","nct_id":"NCT06303713","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=lucarbo-nct06303713. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants will be enrolled in a 3+3 dose escalation design to establish a maximum tolerated dose (MTD) of carboplatin, starting at Dose Level 1 and escalating to Dose Level 2 or 3.\n\n* Baseline visit.\n* Day 1 of Cycles 3 and 5: Tumor assessment radiologic scans.\n* Cycle 1 through End of Treatment:\n\n  * Days 1 and 22 of 42-day cycle: Predetermined dose of carboplatin every 3 weeks for a maximum of up to 6 cycles.\n  * Day 2 of 42-day cycle: Predetermined dose of 177Lu-PSMA-617 every 6 weeks for a maximum of up to 6 cycles.\n* End of treatment visit.\n* Follow up visits in-office or via telephone. If 0 out of 3 participants experience a dose-limiting toxicity (DLT), the study will proceed to the next dose level. If 1 or more participants experience a DLT, this dose level is declared the MTD and study will not proceed to expansion. If 1 out of 6 participants at the highest dose level experience DLTs, this is the recommended Phase 1B dose.","label":"Phase 1A: Dose Escalation","type":"EXPERIMENTAL"},{"description":"19 additional participants will be enrolled at the RP2D of carboplatin and will complete:\n\n* Baseline visit.\n* Day 1 of Cycles 3 and 5: Tumor assessment radiologic scans.\n* Tumor biopsy at baseline and at 12 weeks.\n* Cycle 1 through End of Treatment:\n\n  * Days 1 and 22 of 42 day cycle: Predetermined dose of carboplatin every 3 weeks for a maximum of up to 6 cycles.\n  * Day 2 of 42 day cycle: Predetermined dose of 177Lu-PSMA-617 every 6 weeks for a maximum of up to 6 cycles.\n* End of treatment visit.\n* Follow up visits in-office or via telephone.","label":"Phase 1B: Dose Expansion","type":"EXPERIMENTAL"}],"collaborators":["Novartis"],"completion_date":{"date":"2027-03-19","type":"ESTIMATED"},"conditions":["Prostate Cancer","Metastatic Prostate Cancer","Metastatic Castration-resistant Prostate Cancer"],"enrollment":{"count":37,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Carboplatin","otherNames":["C6H12N2O4Pt","Platinum, diammine [1,1-cyclobutanedicarboxylato(2-)- O,O']-, (SP-4-2)"],"type":"DRUG"},{"name":"177Lu-PSMA-617","otherNames":["Pluvicto","Lutetium Lu 177 vipivotide tetraxetan","C49H71N9O16"],"type":"DRUG"}],"last_update":"2026-04-08","lead_sponsor":"Dana-Farber Cancer Institute","official_title":"LuCarbo - a Phase 1a/1b Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate Cancer","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2026-10-19","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Maximum tolerated dose (MTD) or the Recommended Phase 2 dose (RP2D) of carboplatin administered in combination with 177Lu-PSMA-617","timeFrame":"First 6 weeks of treatment"}],"references":[],"start_date":{"date":"2024-05-22","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate Cancer","url":"https://clinicaltrials.gov/study/NCT06303713"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/lucarbo-nct06303713"}